STOP- CA ランダム化臨床試験

Tomas G Neilan^1,2, Thiago Quinaglia¹, Takeshi Onoue³

¹Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.

JAMA

|August 8, 2023

まとめ

アトロバスタチンは,アントラサイクリン化学療法を受けているリンパ腫患者の心臓機能不全を有意に軽減しました. この研究では,アトルバスタチンは化学療法による心臓疾患を予防することが示唆されています.

科学分野:

心臓病科
腫瘍学
薬理学について

背景:

アントラサイクリンが広く使用されているのがん治療法ですが,心臓機能障害を引き起こす可能性があります.
以前の研究によると,アトルバスタチンはこの副作用を軽減する可能性があります.
がん患者におけるアトルバスタチンの心臓保護効果を確認するために,臨床試験が必要でした.

研究の目的:

アトロバスタチンがリンパ腫患者の心臓機能不全を軽減するかどうかを判断する.
左心室排出分数 (LVEF) の低下に対するアトルバスタチンの影響を評価する.

主な方法:

アントラサイクリン化学療法を受けたリンパ腫患者300人を対象としたダブルブラインドランダム化試験です
参加者はアトルバスタチン (40 mg/ d) またはプラセボを12ヶ月間投与された.
LVEFの低下を12ヶ月間測定して心臓機能をモニタリングした.

主要な成果:

アトルバスタチンは,LVEFの≥10%の減少を55%まで (9%対22%,P=. 002) 減少させた.
プラセボ群では,有意なLVEF減少の確率はほぼ3倍でした.
グループ間で心不全の有意な差は認められなかった.

結論:

アトルバスタチンは,リンパ腫患者の化学療法による心臓機能不全を効果的に軽減しました.
アトロバスタチンの使用は,アントラサイクリン療法による心臓機能障害のリスクが高い患者に支持されています.
長期にわたる心臓発作の発生率を調査する研究も進んでいる.

さらに関連する動画

08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.8K

08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.8K

関連する概念動画

01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

561

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

561

01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

204

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

204

01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

2.9K

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...

2.9K

01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...

関連する実験動画